A refractory anti-NMDA receptor encephalitis successfully treated by bilateral ovariectomy and intrathecal injection of methotrexate and dexamethasone: A case report

Dongmei Wang,Yongming Wu,Zhong Ji,Shengnan Wang,Yunqi Xu,Kaibin Huang,Yu Peng,Hui Zheng,Honghao Wang,Xiaomei Zhang,Suyue Pan
DOI: https://doi.org/10.21203/rs.2.9549/v1
2019-05-13
Abstract:Abstract Background: Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is an autoimmune-mediated disease, which is predominant in young female patients with ovarian teratomas. With proper immunotherapy, most of the patients achieve good prognosis. Nevertheless, some patients may be refractory to first and second-line immunotherapy, thus new treatments are required to help these patients. Case presentation: We present a case of anti-NMDA receptor encephalitis with ovary teratoma. After the prompt removal of the teratoma and strong immunotherapy including intravenous methylprednisolone pulse (IVMP), intravenous immunoglobin (IVIG), plasmapheresis, immunoadsorption, intravenous cyclophosphamide, and rituximab, the patient’s neurologic status did not improve. Bilateral ovariectomy was then conducted and intrathecal injection of methotrexate (MTX) and dexamethasone (DXM) was given. The patient’s neurological symptoms improved dramatically, and she achieved a good prognosis after 23 months. Conclusions: For refractory cases of anti-NMDA receptor encephalitis, intrathecal injection of MTX and DXM may be beneficial. More research is required to elucidate the mechanisms of intrathecal treatment.
What problem does this paper attempt to address?